Alternative schedules with irinotecan

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 12, 2003, Pages 18-24

  Diasio, Robert ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PYRIMIDINE DERIVATIVE;

ADVANCED CANCER; APPETITE DISORDER; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; NEUTROPENIA; PAIN; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; TIME SERIES ANALYSIS; TREATMENT PLANNING; UNITED STATES;

EID: 0141677623     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00330-0     Document Type: Conference Paper

References (19)

1. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
2. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
3. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
4. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
5. Rougier P, Mitry E: Review of the role of CPT-11 in the treatment of colorectal cancer. Clin Colorectal Cancer 2:87-94, 2001
6. For the Irinotecan Study Group, Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 28:905-914, 2000
7. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
8. Saltz LB, Douillard JY, Pirotta N, et al: Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard. Oncologist 6:81-91, 2001
9. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 135:905-914, 2001
10. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001
11. Oncologic Drugs Advisory Committee: Community Audit NDA#220-571. December 8, 2001. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3815b2_01_ pharmacia.pdf (accessed May 22, 2003)
12. Hwang JJ, Marshall JL, Rizvi NA, et al: A study combining irinotecan (CPT-11) and epirubicin (EPI) in advanced solid tumors. Proc Am Soc Clin Oncol 21:78b, 2002 (abstr 2124)
13. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
14. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
15. Drengler RL, Kuhn JG, Schaaf LJ, et al: Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17:685-696, 1999
16. Cassata A, Stani SC, Alù M, et al: Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 20:144a, 2001 (abstr 573)
17. Schleucher N, Tewes M, Achterrath W, et al: Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 20:141a, 2001 (abstr 561)
18. Ratain MJ: Irinotecan dosing: Does the CPT in CPT-11 stand for "can't predict toxicity"? J Clin Oncol 20:7-8, 2002
19. Diasio RB, Johnson MR: Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5:2672-2673, 1999